» Articles » PMID: 37638007

Deciphering the Crosstalk of Immune Dysregulation Between COVID-19 and Idiopathic Inflammatory Myopathy

Overview
Journal Front Immunol
Date 2023 Aug 28
PMID 37638007
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The coronavirus disease (COVID-19) pandemic is a serious threat to public health worldwide. Growing evidence reveals that there are certain links between COVID-19 and autoimmune diseases; in particular, COVID-19 and idiopathic inflammatory myopathies (IIM) have been observed to be clinically comorbid. Hence, this study aimed to elucidate the molecular mechanisms of COVID-19 and IIM from a genomic perspective.

Methods: We obtained transcriptome data of patients with COVID-19 and IIM separately from the GEO database and identified common differentially expressed genes (DEGs) by intersection. We then performed functional enrichment, PPI, machine learning, gene expression regulatory network, and immune infiltration analyses of co-expressed genes.

Results: A total of 91 common genes were identified between COVID-19 and IIM. Functional enrichment analysis revealed that these genes were mainly involved in immune dysregulation, response to external stimuli, and MAPK signaling pathways. The MCODE algorithm recognized two densely linked clusters in the common genes, which were related to inflammatory factors and interferon signaling. Subsequently, three key genes (CDKN1A, IFI27, and STAB1) were screened using machine learning to predict the occurrence of COVID-19 related IIM. These key genes exhibited excellent diagnostic performance in both training and validation cohorts. Moreover, we created TF-gene and miRNA-gene networks to reveal the regulation of key genes. Finally, we estimated the relationship between key genes and immune cell infiltration, of which IFI27 was positively associated with M1 macrophages.

Conclusion: Our work revealed common molecular mechanisms, core genes, potential targets, and therapeutic approaches for COVID-19 and IIM from a genomic perspective. This provides new ideas for the diagnosis and treatment of COVID-19 related IIM in the future.

Citing Articles

Machine learning and experiments revealed a novel pyroptosis-based classification linked to diagnosis and immune landscape in spinal cord injury.

Zhang Z, Zhu Z, Liu D, Wang X, Liu X, Mi Z Heliyon. 2024; 10(3):e24974.

PMID: 38314301 PMC: 10837564. DOI: 10.1016/j.heliyon.2024.e24974.


Macrophage states: there's a method in the madness.

Katkar G, Ghosh P Trends Immunol. 2023; 44(12):954-964.

PMID: 37945504 PMC: 11266835. DOI: 10.1016/j.it.2023.10.006.

References
1.
Healey Q, Sheikh A, Daines L, Vasileiou E . Symptoms and signs of long COVID: A rapid review and meta-analysis. J Glob Health. 2022; 12:05014. PMC: 9125197. DOI: 10.7189/jogh.12.05014. View

2.
Cantu N, Vyavahare S, Kumar S, Chen J, Kolhe R, Isales C . Synergistic Effects of Multiple Factors Involved in COVID-19-dependent Muscle Loss. Aging Dis. 2022; 13(2):344-352. PMC: 8947833. DOI: 10.14336/AD.2021.0817. View

3.
Espinosa-Ortega F, Gomez-Martin D, Santana-de Anda K, Romo-Tena J, Villasenor-Ovies P, Alcocer-Varela J . Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets. Clin Exp Immunol. 2014; 179(3):520-8. PMC: 4337684. DOI: 10.1111/cei.12475. View

4.
Shimizu H, Matsumoto H, Sasajima T, Suzuki T, Okubo Y, Fujita Y . New-onset dermatomyositis following COVID-19: A case report. Front Immunol. 2022; 13:1002329. PMC: 9637802. DOI: 10.3389/fimmu.2022.1002329. View

5.
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L . Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open. 2022; 8(2). PMC: 9471207. DOI: 10.1136/rmdopen-2022-002508. View